(Q36445636)

14 August 2017

1 reference

title

Human genetic variability and HIV treatment response (English)

1 reference

14 August 2017

David W Haas

1

1 reference

14 August 2017

language of work or name

1 reference

1 July 2006

1 reference

14 August 2017

published in

Current HIV/AIDS reports

1 reference

14 August 2017

volume

3

1 reference

14 August 2017

issue

2

1 reference

14 August 2017

page(s)

53-58

1 reference

https://scigraph.springernature.com/pub.10.1007/s11904-006-0018-x

14 August 2017

exact match

0 references

cites work

A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11904-006-0018-X

Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?

21 January 2018

1 reference

12 December 2020

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

1 reference

12 December 2020

MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study

1 reference

12 December 2020

The role of TNF alpha in adipocyte metabolism.

1 reference

12 December 2020

Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene

1 reference

12 December 2020

Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.

1 reference

12 December 2020

The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys

1 reference

12 December 2020

Hypersensitivity related to abacavir in two members of a family

1 reference

12 December 2020

Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study

1 reference

12 December 2020

HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5

1 reference

12 December 2020

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

1 reference

12 December 2020

Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response

1 reference

12 December 2020

Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6

1 reference

12 December 2020

The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity

1 reference

12 December 2020

Tumour necrosis factor-alpha gene -238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy

1 reference

12 December 2020

Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance

1 reference

12 December 2020

Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.

1 reference

12 December 2020

Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts

1 reference

12 December 2020

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

1 reference

12 December 2020

Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study

1 reference

12 December 2020

Identification of a major co-receptor for primary isolates of HIV-1

1 reference

12 December 2020

The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells.

1 reference

12 December 2020

Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance

1 reference

12 December 2020

Alleles of the gene encoding IL-1alpha may predict control of plasma viraemia in HIV-1 patients on highly active antiretroviral therapy

1 reference

12 December 2020

Risk factor analysis of hypersensitivity reactions to abacavir

1 reference

12 December 2020

Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study

1 reference

12 December 2020

Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts

1 reference

12 December 2020

Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection

1 reference

12 December 2020

Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients

1 reference

12 December 2020

HIV-1 protease inhibitors and the MDR1 multidrug transporter

1 reference

12 December 2020

Population pharmacokinetic meta-analysis with efavirenz

1 reference

12 December 2020

Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders

1 reference

12 December 2020

Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study

1 reference

12 December 2020

Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters

1 reference

12 December 2020

TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy

1 reference

12 December 2020

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

1 reference

12 December 2020

Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy

1 reference

12 December 2020

Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression

1 reference

12 December 2020

AP-3 directs the intracellular trafficking of HIV-1 Gag and plays a key role in particle assembly

1 reference

12 December 2020

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors

1 reference

12 December 2020

MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients

1 reference

12 December 2020

Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor

1 reference

12 December 2020

Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant

1 reference

12 December 2020

Mechanism of indinavir-induced hyperbilirubinemia

1 reference

12 December 2020

Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver

1 reference

12 December 2020

10.1007/S11904-006-0018-X

Identifiers

DOI

1 reference

14 August 2017

1 reference